C4 Therapeutics vs Editas Medicine
Editas Medicine reported revenue of $40 million in fiscal 2025, about the same as C4 Therapeutics' $36 million in fiscal 2025. C4 Therapeutics' revenue grew 1.0% in its latest year, and Editas Medicine's grew 25.4%. C4 Therapeutics had an operating margin of -320.5%, against -394.9% at Editas Medicine. Free cash flow was −$99 million at C4 Therapeutics and −$166 million at Editas Medicine.
Side by side
| C4 Therapeutics | Editas Medicine | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $36M | $40M |
| Revenue growth | 1.0% | 25.4% |
| Revenue growth a year, last 5 years | — | −14.9% |
| Gross margin | — | — |
| Operating margin | −320.5% | −394.9% |
| Net margin | −292.1% | −395.0% |
| Free cash flow | −$99M | −$166M |
| Free cash flow margin | −276.2% | −409.3% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.5% | 7.8% |
| Last close | $2.44 | $1.71 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $22,200 | sold $106,705 |
| Piotroski F-score | 3 of 8 | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
C4 TherapeuticsEditas Medicine
Operating margin
Percent of revenue
C4 TherapeuticsEditas Medicine
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
C4 TherapeuticsEditas Medicine
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the C4 Therapeutics and Editas Medicine pages.